title: SPET investigations in extrapyramidal diseases using specific ligands.
abstract: Single photon emission tomographic investigations of the extrapyramidal system have become easier to perform since the development of the ligands [123I]-beta-CIT and [123I]-IBZM. Thirty-three patients were investigated with [123I]-IBZM. The images were evaluated visually and semi-quantitatively (ratio of the striatum to front cortex). Ten controls showed a mean (+/- S.D.) ratio of 1.513 +/- 0.06; nine patients with Parkinson's disease had a smaller ratio of 1.425 +/- 0.095; six patients with Huntington's disease had a significantly lower ratio (1.147 +/- 0.105). Eight patients were not classified, because of different nosologic entities. Twenty-three patients were investigated with [123I]-beta-CIT. They were evaluated using standard techniques and the ratio of the striatum to cerebellum. Six controls had a mean ratio of 5.128 +/- 0.787. In 11 Parkinson patients, the ratio was significantly less (3.359 +/- 0.769). Patients with focal dystonia showed normal values. One patient with Huntington's disease had a significantly lower ratio. Receptor studies of the extrapyramidal system may help with diagnoses and could be of relevance therapeutically.
authors.affiliation: Department of Neurology, Landesnervenklinik Salzburg, Austria.
authors.forename: W
authors.initials: W
authors.lastname: Staffen
authors.forename: N
authors.initials: N
authors.lastname: Hondl
authors.forename: E
authors.initials: E
authors.lastname: Trinka
authors.forename: R
authors.initials: R
authors.lastname: Zenzmaier
authors.forename: G
authors.initials: G
authors.lastname: Ladurner
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides / Q000493:pharmacokinetics; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D003042:Cocaine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D018492:Dopamine Antagonists / Q000493:pharmacokinetics; D006527:Hepatolenticular Degeneration / Q000000981:diagnostic imaging / Q000378:metabolism; D006801:Humans; D006816:Huntington Disease / Q000000981:diagnostic imaging / Q000378:metabolism; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000000981:diagnostic imaging* / Q000378:metabolism; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000378:metabolism; D011759:Pyrrolidines / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000032:analysis*; D012016:Reference Values; D013494:Supranuclear Palsy, Progressive / Q000000981:diagnostic imaging / Q000378:metabolism; D014018:Tissue Distribution; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
chemical_list: D001549:Benzamides; D018492:Dopamine Antagonists; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C069723:2beta-carbomethoxy-3beta-(4-iodophenyl)tropane; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D003042:Cocaine